EGFR 突变型晚期非小细胞肺癌患者治疗应答和表皮生长因子受体酪氨酸激酶抑制剂的伴随遗传改变。
Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.
机构信息
State Key Laboratory of Oncology in South China, Guangzhou.
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
出版信息
JAMA Oncol. 2018 May 1;4(5):739-742. doi: 10.1001/jamaoncol.2018.0049.
Abstract
This cohort study examines the association of concomitant genetics alterations with response to treatment with epidermal growth factor receptor tyrosine kinase inhibitors among patients with -mutant advanced non–small cell lung cancer.
摘要
本队列研究探讨了 - 突变型晚期非小细胞肺癌患者中伴随的基因改变与表皮生长因子受体酪氨酸激酶抑制剂治疗反应之间的关系。
相似文献
1
Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.EGFR 突变型晚期非小细胞肺癌患者治疗应答和表皮生长因子受体酪氨酸激酶抑制剂的伴随遗传改变。
JAMA Oncol. 2018 May 1;4(5):739-742. doi: 10.1001/jamaoncol.2018.0049.
2
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
3
Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.利用循环肿瘤 DNA 靶向测序技术无创检测晚期非小细胞肺癌的可操作突变。
Lung Cancer. 2018 Oct;124:154-159. doi: 10.1016/j.lungcan.2018.08.007. Epub 2018 Aug 8.
4
[The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].[伴随基因改变对表皮生长因子受体敏感突变的晚期非小细胞肺癌患者中表皮生长因子受体酪氨酸激酶抑制剂治疗疗效的影响]
Zhonghua Jie He He Hu Xi Za Zhi. 2018 Oct 12;41(10):778-782. doi: 10.3760/cma.j.issn.1001-0939.2018.10.006.
5
Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer.循环血浆微小RNA作为鉴定晚期非小细胞肺癌患者表皮生长因子受体（EGFR）突变状态及监测表皮生长因子受体-酪氨酸激酶抑制剂治疗的潜在标志物。
Oncotarget. 2017 Jul 11;8(28):45807-45824. doi: 10.18632/oncotarget.17416.
6
Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters.晚期表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）患者的治疗：测序至关重要。
Pulmonology. 2019 Sep-Oct;25(5):306-309. doi: 10.1016/j.pulmoe.2019.04.005. Epub 2019 Jun 7.
7
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.表皮生长因子受体（EGFR）突变的非小细胞肺癌在一线酪氨酸激酶抑制剂治疗中出现疾病进展时的优化管理。
Lung Cancer. 2017 Aug;110:7-13. doi: 10.1016/j.lungcan.2017.05.009. Epub 2017 May 11.
8
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor ()-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.波齐替尼在对表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂产生耐药的EGFR突变型肺腺癌患者中的II期研究。
Cancer Res Treat. 2017 Jan;49(1):10-19. doi: 10.4143/crt.2016.058. Epub 2016 May 3.
9
Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.物理尺寸对携带 EGFR 突变的非小细胞肺癌患者吉非替尼疗效的影响。
Lung Cancer. 2013 Sep;81(3):435-439. doi: 10.1016/j.lungcan.2013.05.021. Epub 2013 Jul 1.
10
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.表皮生长因子受体（EGFR）突变、间变性淋巴瘤激酶（ALK）重排以及EGFR/ALK共同改变的晚期非小细胞肺癌患者的临床结局
Oncotarget. 2016 Oct 4;7(40):65185-65195. doi: 10.18632/oncotarget.11218.
引用本文的文献
1
Comparative analysis of first-generation epidermal growth factor receptor inhibitors combined with chemotherapy versus third-generation epidermal growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis.第一代表皮生长因子受体抑制剂联合化疗与第三代表皮生长因子受体抑制剂治疗晚期非小细胞肺癌的比较分析：一项系统评价和荟萃分析
Front Pharmacol. 2025 Aug 14;16:1586332. doi: 10.3389/fphar.2025.1586332. eCollection 2025.
2
What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review.晚期表皮生长因子受体（EGFR）突变的非小细胞肺癌的最佳一线联合治疗方案是什么：一项网状Meta分析和系统评价
Front Pharmacol. 2025 Aug 11;16:1572115. doi: 10.3389/fphar.2025.1572115. eCollection 2025.
3
Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene Alterations.非小细胞肺癌对靶向治疗的差异反应：单表皮生长因子受体（EGFR）突变与并发基因改变患者结局的比较分析
Appl Clin Genet. 2025 Jul 31;18:153-164. doi: 10.2147/TACG.S531337. eCollection 2025.
4
Elevated plasma HSP90α as a prognostic marker in EGFR-mutant non-small cell lung cancer.血浆HSP90α升高作为表皮生长因子受体（EGFR）突变的非小细胞肺癌的预后标志物
Oncol Lett. 2025 Jul 22;30(4):457. doi: 10.3892/ol.2025.15203. eCollection 2025 Oct.
5
Prediction of the efficacy and clinical prognosis of first-line EGFR-tyrosine kinase inhibitors in non-small cell lung cancer patients based on ΔCt values derived from the super-amplification refractory mutation system (ARMS): a real-world retrospective study.基于超扩增难治性突变系统（ARMS）衍生的ΔCt值预测非小细胞肺癌患者一线表皮生长因子受体酪氨酸激酶抑制剂的疗效和临床预后：一项真实世界回顾性研究
J Thorac Dis. 2025 Jun 30;17(6):3897-3911. doi: 10.21037/jtd-2025-97. Epub 2025 Jun 25.
6
[Analysis of Risk Factors for Meningeal Metastasis in Patients
with Lung Adenocarcinoma Following Non-surgical Interventions].[非手术干预后肺腺癌患者脑膜转移的危险因素分析]
Zhongguo Fei Ai Za Zhi. 2025 Apr 20;28(4):267-280. doi: 10.3779/j.issn.1009-3419.2025.101.06.
7
Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC.第一代表皮生长因子受体酪氨酸激酶抑制剂联合低剂量贝伐单抗与奥希替尼治疗未经治疗的晚期表皮生长因子受体突变型非小细胞肺癌的比较
Ann Med. 2025 Dec;57(1):2493766. doi: 10.1080/07853890.2025.2493766. Epub 2025 Apr 25.
8
Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring 21 L858R mutation.携带21 L858R突变的晚期非小细胞肺癌患者一线EGFR-TKI疗效的真实世界预后因素。
Glob Med Genet. 2025 Feb 19;12(2):100051. doi: 10.1016/j.gmg.2025.100051. eCollection 2025 Jun.
9
A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with mutation-positive non-small cell lung cancer.对表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂治疗EGFR突变阳性非小细胞肺癌患者的贝叶斯网络荟萃分析。
Cancer Pathog Ther. 2024 Jun 21;3(2):135-146. doi: 10.1016/j.cpt.2024.06.004. eCollection 2025 Mar.
10
Unravelling the complexity of -mutated lung adenocarcinoma: a unique case report with histological transformations and co-alteration acquisition.解析 - 突变型肺腺癌的复杂性：一例具有组织学转变和共改变获得的独特病例报告
Transl Lung Cancer Res. 2025 Feb 28;14(2):639-648. doi: 10.21037/tlcr-24-707. Epub 2025 Feb 27.
本文引用的文献
1
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
2
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.晚期表皮生长因子受体（EGFR）突变型肺癌中共发基因改变的演变及其临床影响
Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.
3
Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.通过靶向测序在晚期非小细胞肺癌患者中鉴定出的循环肿瘤DNA。
Cancer Lett. 2016 Jan 28;370(2):324-31. doi: 10.1016/j.canlet.2015.11.005. Epub 2015 Nov 12.
4
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.表皮生长因子受体（EGFR）特定突变与临床特征对 EGFR 突变型肺癌患者接受 EGFR 酪氨酸激酶抑制剂与化疗治疗后结局的影响：一项荟萃分析。
J Clin Oncol. 2015 Jun 10;33(17):1958-65. doi: 10.1200/JCO.2014.58.1736. Epub 2015 Apr 20.
5
Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.表皮生长因子受体酪氨酸激酶抑制剂与野生型表皮生长因子受体非小细胞肺癌的传统化疗：荟萃分析。
JAMA. 2014 Apr 9;311(14):1430-7. doi: 10.1001/jama.2014.3314.
6
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
Zotero 插件